# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company d...
New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPARSAN DIEGO, CA / ACCE...
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $...
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of...
Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to ...